EXTREMELY LOW DOSES OF ANTIBODIES TO THE C-FINAL FRAGMENT OF β -SUBUNIT INSULIN RECEPTOR ARE THE NEW CLASS OF ORAL BLOOD GLUCOSE-LOWERING AGENTS
Bation (antibodies to the C-final fragment of β-subunit insulin receptor in extremely low doses, a mixture of homoeopathic dilutions of С12+С30+С200, «Scientific and Industrial Manufacturer «Materia Medica Holding», Limited Liability Venture, Russia), is a novel drug developed to treat type II diabetes. A conducted clinical trial showed that the drug was effective and safe when used in patients with type II diabetes of moderate severity. Bation was not inferior to Glibenchlamide in its clinical effectiveness and was superior to the drug to be compared in producing a positive effect on the index of НОМА-IR, fasting insulinemia, as well as BMI. Taking into account the effectiveness and safety of this drug, Bation can be recommended as a prescription drug for patients with moderate forms of type II diabetes when disturbance of carbohydrate metabolism is moderately manifested.